The first-generation NNRTIs (efavirenz, delavirdine, and nevirapine) have a low genetic barrier to resistance and single mutations in the HIV-1 reverse transcriptase lead to class-wide resistance and virological failure.1 Generally, after treatment failure or development of toxicity, NNRTIs are replaced by ritonavir-boosted protease inhibitors
We focus on: Advanced Bioavailability: Using liposomal delivery to ensure nutrients reach your cells
Cysteine form of thiloate (N-acetyl-l-cysteine) will be used to replenish the glutathione concentration by the liver [17]
Archives of Internal Medicine
Elsevier, Amsterdam, pp 431434 Goldin L, Gershon E, Lake C, Murphy D, McGinniss M, Sparkes R (1982) Segregation and linkage studies of plasma dopamine-beta-hydroxylase (DBH), erythrocyte catechol-O-methyltransferase (COMT), and platelet monoamine oxidase (MAO): possible linkage between the ABO locus and a gene controlling DBH activity
It is supplied strictly for laboratory research and scientific investigation only not for human consumption, clinical use, or therapeutic application
